Compare Crispr Therapeutics AG (CRSP) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Quantum Computing Inc — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Quantum Computing Inc trades at $8.89 (market cap $2.03B). The key difference: Crispr Therapeutics AG is far larger — about 2.6× Quantum Computing Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | QUBT | |
|---|---|---|
Market Cap | $5.23B | $2.03B |
Sector | Health | Technology |
52-Week High | $76.78 | $24.62 |
52-Week Low | $44.34 | $6.31 |
Enterprise Value | $3.65B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Quantum Computing Inc. (QUBT) trades at $8.92, down slightly by 0.11% on the day, with a bearish technical signal. The company is in a high-growth but pre-profit phase, reporting Q2 2026 revenue of $5.6 million (MarketBeat, 2026-08-10), a significant increase, but with persistent net losses. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, indicating substantial upside potential from current levels.
The outlook for QUBT is speculative, offering high growth potential in quantum computing and photonics, supported by strong institutional interest and revenue expansion. Key risks include steep valuation (P/S of 189.05), ongoing losses, high cash burn, and competitive pressures in the emerging quantum sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
